Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.22)
# 4,024
Out of 4,789 analysts
36
Total ratings
13.33%
Success rate
-31.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Reiterates: Overweight | n/a | $17.64 | - | 12 | Mar 12, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $83 | $31.52 | +163.32% | 2 | Dec 9, 2024 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $60.70 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $6.66 | +876.71% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $0.84 | - | 1 | Nov 8, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $22 | $4.14 | +432.04% | 3 | Sep 13, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $1.13 | +1,138.94% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $33.14 | +222.87% | 4 | Aug 8, 2022 |
Beam Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.64
Upside: -
Legend Biotech
Dec 9, 2024
Reiterates: Overweight
Price Target: $83
Current: $31.52
Upside: +163.32%
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $60.70
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $6.66
Upside: +876.71%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.84
Upside: -
Verve Therapeutics
Sep 13, 2023
Reiterates: Neutral
Price Target: $22
Current: $4.14
Upside: +432.04%
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $1.13
Upside: +1,138.94%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $33.14
Upside: +222.87%